EFTA00506070.pdf

EFTA00506070  Corporate Overview • Mission: To improve the health of patients suffering from serious diseases and unmet medical needs of viral origin and to build shareholder value by developing new antiviral therapies • Founded: 2006 • Raised: $36m • Ownership: Privately Held • Headquarters: San Francisco, CA 2 BcisL:er 2 EFTA00506071  2013-08-22 Epiphany Biosciences' Investment Thesis • Late-stage clinical antiviral company with two attractive, high-potential candidates • EP8-348 is a proven drug candidate with multiple "shots-on-goal" • Safe and effective small molecule with broad spectrum antiviral activity • fin competition for unmet medical needs • No antiviral approved for shingles associated pain • No approved antivirals for EBV • Paradigm-changing therapeutic approach to a variety of serious diseases, incl. orphan indications • EP8.510 is a Nucleotide Polymerase Inhibitor (NPI) for HCV with a highly competitive preclinical profile versus other high profile leading NPIs • Streamlined and efficient development and clinical plans • Able to achieve major value-inflection points in multiple clinical programs in approximately 1.2 years • Highly experienced team with track record of success Epphary 3 • &oscences Add spreadsheet details 3 EFTA00506072  Epiphany's product pipeline Program 2013 2014 2015 2016 2017 2018 2019 l Il l EPB-348 I VZV-Shingles Pt 2t0Pi r Tra Pi Items; TT.I Atcrvo3 Mao Clogintrg -I — EBV-Transplant Pe 2 rns M2 Tsar AttmN 2Wvow Gettateg EBV.Autoimmune (Multiple Sclerosis) Dark Tam Pet MI n Ph 3Tila1—n EBV-Autolnunune (Idiopathic Pulmonary Fibrosis) nabs I Ph 3 TM EBV.OncologYINasal Pharyngeal Carcinoma) maim Pb3ins EPB-510 Hepatitis C RUMS mita Pons S 4 4 EFTA00506073 Valomaciclovir Stearate (EPB-348): Epiphany's late-stage product opportunity EPB-348 is an effective, late-stage small molecule antiviral • Safe and effective small molecule with broad spectrum antiviral activity including Varlcella Zoster Vitus (V2V), Epstein.Barr Virus IEBV), & Herpes Simplex 1 and 2 (HSV-1/2) History of Valomadclovir Stearate (EPB-348) • EPB-348 invented by MedMr AB (MIV.606) • Ucensed to Abbott laboratories- developed through Phase 2a (ABT-606) • Ucensed to Reliant Pharmaceuticals -developed tablet formulation (RP-606) • Ucensed to Epiphany Biosciences - completed key Shingles & EBV proof-of.concept Phase 2 studies Proven antiviral activity, dinical impact, & safety in multiple Phase 1 & 2 trials • Successful Phase 2b trial for shingles met primary endpoint • Successful Phase 2 trial for EBV and infectious mononucleosis met primaryendpoint Highly favorable safety profile • EPB-348 has been dosed to more than 720 patients • Mete than 130 patients have received multiple doses of 3 grams or more • No maximum tokratod dose yet determined Well characterized mechanism of action • Selective viral DNA-polymerase inhibitor • Up to 400-times more potent than Acydovir with better Intracellular concentrations and half-lives 5 EFTA00506074  2013-08-22 Strong in vitro & preclinical data provide consistent rationale why EPB-348 is more potent than other antivirals Active Drug VZV Welts 1j1 • EP8-348 l. • 142G thkintsciclovii Stn. wal YAsDNA iptoditvg) Thyrnitine Polymerise Kings.O H2G has improved cellular permeability, a faster phosphorylation rate, and better intracellular stability and persistence • Against a variety of different WV strains in vitro, H2G is up to 400x more potent than acyclovir (ACV) • H2G is approx. 250x-better substrate for VZV encoded thymidine kinase than ACV • The intracellular concentration of H2G-TP is more than 140x greater than ACV-TP • H2G-TP has a longer Tx than ACV-TP • EPB-348 has excellent activity in the gold-standard in vivo Simian Varicella Virus monkey model Lon. MI *I Atnntrts Amen O•nativr. AMU Itale.G Man. &an Poilater. MIL; MI; Ws. V! nehlrelacca Agents Oman., 11XL.17,1170. 6 6 EFTA00506075 Valomaciclovir Stearate (EPB-348) Lead Indication: Shingles & Shingles-Associated Pain Epiphany Biosciences 7 EFTA00506076  2013-08-22 EPB-348 can address the important unmet needs of shingles Differentiating advantages of EPB-348 for shingles • Shingles/Zoster associated pain impact • Wider treatment window • Simpler dosing regimen Proven shingles efficacy • EPB-348 met Phase 2b Shingles Trial endpoints At lower, less frequent doses, EPB-348 was statistically non-inferior to higher dose Valtrex • Data is directionally consistent with dose dependent improvement De-risked & cost effective late stage clinical development plan • Ability to go against placebo for pain and antiviral endpoints in Phase 3 trials • Phase 3 trials cost significantly offset if performed in countries with =credits • No competing shingles trials actively recruiting 8 EFTA00506077  Phase 2b shingles study designed to show EPB-348 efficacy versus Valacyclovir Screening 72 h Rankrrinsion Days 2.7 Days 8.28 Days 29-120 Treatment Fdlow.up• Follow-up“ Ertl-3431 lg QD, 2g QD, Treatment Regimen EPB348 am ictig , —VV 1 g TID, Masan Study De* 0 Non infericoty stud/ (Valac,olovir as comparator) Endpoints O60% powered with respect toprimly endpoint O primary: Time to complete crusting O Rardomued, double-Wind, acuve-contnolled,mulb-center. parallel-group O Secondary: Time to complete cassaben o pain OOyeral safety parameters 006 U.S. dowel centers °Patients were Followed for three maths with up to IS mots • Day 28 Final Vise for patients wd rash & pain resolution O Baseine demographics homogeneous& babnced across treatment group ** for patients with oilcans rash or pain at Day 28 0373 immunocompetent adult pabents randomized into 4 sroups .3s any for Pit purposes. Data mduded n final analysis 9 9 EFTA00506078  EPB-348 met Phase 2b primary antiviral endpoint of time-to-complete crusting versus Valacyclovir • EPB-348 once-a-day was statisticallynon-inferior or ;superior to valacyclovir hree- times-a-day in both the ITT and PP populations for time to complete cru Ling by day 28 EPB-348 EPB-348 (1,8-34S Valacycloylr Parameter 1000 mg 2000 mg 3000 mg 1000 mg Once a day Once a day Once a day Three times a day Patient age .. 218 .18 250 218 218 250 218 218 250 218 218 2S0 nose IVA.) Analysis ITT PP ITT ITT PP ITT ITT PP ITT ITT PP ITT Number of 11S 102 72 117 107 74 II 16 12 109 1CO 6/ Patients INI Mean 11.1 11.3 11.2 10.7 10.7 11.2 2.2 7.5 7.2 11.5 116 122 (SO 10.77) ( 0.77) (096) (na) (ida) (0141 11.06) was) n4s) (0.79) (0.11) (1.03) Confidence .1,842, .2.470, .3.372, -2243, -2295, -3.791. .8.252, 6.190, -10.231. Interval 2.501 1.942 2.239 1.192 1.255 1.406 4.345 .0.073 -0.229 P.value 0491 0.601 0.949 0.597 0.571 0.337 0.006 0.019 0.009 (unadjusted, Pei "/,umnslon wows .1cycbor lot th•intatment dumb.norm bale in insunotanipelatt Sub ArrmnW& dead. bind Alsomorttaled tat TV, t nni MC4 Wol 2012.Sa 1224. 10 7 10 EFTA00506079  Statistically superior time to complete cessation of pain for patients with pain at Day 28 • Patients who still had pain on Day 28 and were treated with EP8-348 (2 g QD) had a statistically s'gnificant 'shorted time to pain resolution by nearly 2 weeks than the valacydovir control group (ITT) EPB-MS EPS 348 Valacydovir Paramet 1000 mg 2000 mg 1000 mg Once &day Once a day Three limes a day Patient age 118 250 318 250 :1a range (y.o.) Number of 28 21 29 23 23 20 patients (N) Mean 47.9 as 33.1 31.4 46.3 47.2 )SE) 16.00) 14.39) (4.711 (5.041 15.601 IS 21) Confidence 10.265, (32.010, (1.033, 1.33.106. Interval 2.410) .3.087) 5.976) 0.4741 P-value 0.133 0.047 0.034 (umadJusled) 11 EFTA00506080  Incidence of any pain in ≥50 year old patients was consistently lower for EPB-348 compared to Valacyclovir Vaster Associated Pain (ZAP) nwhi. (semi cEP04Ot2900) $ 0 9) 30 60 90 120 0y Day • There is a natural resolution of pain in a subset of patients with shingles • Antiviral treatment can reduce the incidence of pain and improve time to pain cessation 12 12 EFTA00506081  EPB-348 retains its efficacy on day 3 after rash, suggesting a wider treatment window • EPB-348 has statistically significant o time to complete crusting on )Day 3 for those 50 years and older compared to :0yir 1( TT) EPB-348 EPB-348 Varacyclovir Parameter 1000 mg 2000 mg 1000 mg Once a day Once a day Twee times a day Patient age 218 2 SO z18 z50 218 250 range (y.0.) Noun 048 4472 048 4472 048 68.n 048 445-72 0-08 4472 ea 48-72 Number of 78 32 50 22 80 3? 41 2? 75 34 43 24 patients (N) Mean 12.7 101 12.1 11.1 10.5 11.2 11.2 11.2 10.8 13.3 10.5 16.1 (SE) (9.51 ISM 11.23) (1.62) (1.21 (2.2) (1.0SI 11.42) 17.5) WO (1.121 1149) P-value 0.11 0.14 0.152 0.012 0.39 0.59 0.775 0.051 3 13 EFTA00506082  EPB-348 has consistently proven to be a more potent antiviral than Valacyclovir for shingles In vitro • H2G is up to 400-times more active than ACV against the shingles virus In vivo • EPB-348 is more effective against SW in a monkey infection model compared to ACV Clinical • Phase 2a clinical shingles trial (Abbott) • Study showed a 10% decrease In pain duration with 750 mg BID, compared to acyclovir EP8-348 EPB-348 M8-348 Acyclevfr Parameter 230 mg MO mg 730 mg 800 mg Take a day Twice a day Twice a day Flue times a day N 21 20 17 21 Median (d) 109 107 106 150 Phase 2b clinical shingle trial (Epiphany) • 1 g EPB-348 QD Is stall tkally non-Inferior to 1g Valtrex TID (3g total) for time-to-complete crusting IPP) • 2g EPB-348 QD had a statistically significant shorter time to pain resolution for patients • No efficacy dropoff (or dosing on Day 3 for EPB-348 (182 g) unlike Valtrex TID (3g total) 14 EFTA00506083  2013-08-22 EPB-348 appears to be very safe Results to-date show EPB-348 to be safe and well tolerated • EPB-348 has been dosed to more than 720 patients • More than 130 patients have received multiple doses of 3 grams or more Phase 2b Safety Highlights • No study drug discontinuations due to related adverse events • Patients with compromised renal function tolerated the drug very well • Side-effects were similar between treatment groups and generally mild in nature • Two discontinuations from the study based on adverse events deemed not related to study drug • Three serious adverse events; all deemed not related to study drug (blind maintained) 15 15 EFTA00506084  2013-08-22 Phase 2b/3 pivotal shingles trial to be focused on demonstrating key point of pain differentiation According to the FDA, Valtrex and Famvir have not shown any statistical differences compared to control for pain • Consequently, EPB-348 Phase 2b/3 trials can go against placebo for both antiviral (cutaneous) and pain endpoints Previous clinical studies with Acyclovir, Valtrex and Famvir suggest that they may have some impact on reducing pain & PHN • The pain impact of these antivirals have not been proven in sufficiently powered prospective studies • Use of higher dose levels of these less potent antivirals is not possible as they are already dosed near their maximum approved dosage levels Since EPB-348 is MOM effective against shingles than Valtrex across a variety of parameters, it is anticipated that EPB-348 could meet both pain and antiviral endpoints in Phase 2b/3 trials, especially against placebo 16 16 EFTA00506085  Phase 2b/3 pivotal shingles pain trial design & milestones Screening RandcakaSon 7-day 143-day 72 h treatment follow-up EPB-348 2g BID Treatment Regimen • Placebo Study Design • Double-blinded, placebo controlled • Patients aged 50 to 80 years old • Primary endpoint: incidence of pain at Day 60 Milestones • 7-month enrollment period • 5 month subject participation period • 1-Month from Last patient out to database lock • 1-Month from database lock to topline data Highly cost-efficient clinical trial plan • Example: Australia has 615% rebate/tax credit • No competing shingles trials actively recruiting 17 17 EFTA00506086  2013-08-22 Shingles is the first target market for EPB-348, growing to more than $1 Billion Market Potential (in Smillions)' • Sales volume in the major pharmaceutical markets projected to 1/04 grow to >$1 billion (IMS) 120> • Key demographic of patients >60 years old is growing with the aging of the 5:01 global population flak., Annual incidence of shingles in over 60 OEU 10 population is 1.1% OUS 408 • Projected 38% growth in the number of shingles patients over 60 years old in 108 the Asian markets by 2020, including >5.4 million cases in China 2018 ... 2012 2019 2014 2015 1018 1011 1018 1010 1020 1011 1011 • Branded drugs dominate the worldwide markets solely on perceived dosing convenience and effective sales and marketing (GSK) Some. IMS extrapolated nog governmental demographic prcleebons 18 I 18 EFTA00506087  EPB-348's advantages for shingles would allow it to dominate the market Existing shingles antivirals • No shingles oain heneflit • According to the FDA, Valtrex and Famvir have not shown any statistical differences compared to control for pain • Narrow Mensal& Index: Approved dosages for shingles are very close to maximum approved dose • imited treatment window: Must be administered within 72 hours of shingles rash onset & efficacy drops off significantly when administered between ag-72 hours • Complicated dosing regimens: Acyclovir: S-times a day; Value< • & Famvir': 3 times a day Shingles Vacdne • Minimal market impact of only 1-2% • High co-pay, limited efficacy, unapproved for immunocompromised and those less than 50 years old • From 2007-2009, lostavax • uptake was extremely low at 3.9% (Langan, SM et of PLOS 2013) Unapproved shingles antiviral, • ASP-2151: Hellcase Inhibitor development officially suspended in 2011because of toxicity • FY-100: No dinical or In vivo demonstration of efficacy • No apparent dinkal evidence of FV-100 antiviral activity In Phase 2 trial • No statistical endpoints achieved with respect to pain in Phase 2 trial • Mechanism of action is unknown & no antiviral activitydemonstrated in standard ,n who models L9 19 EFTA00506088  EPB-348 can be marketed for shingles with a small sales force & with the possibility of early revenues = MI Myth: A large primary-care sales force is required for shingles • A small sales force on focus on tertiary care centers that see high- volumes of patients such as the urban elderly • Anticipate sales of approximately of $200 m using this focused approach • Use at tertiary centers will drive further market expansion Revenue after Phase 2b/3 Shingles trial & Ph 2 EBV-transplant may be possible as part of Named Patient Programs 2 a 20 EFTA00506089  Valomaciclovir Stearate (EPB-348) Second Indication: Epstein-Barr Virus (EBV) & Transplant __ 11 IIIIIIIIII 21 EFTA00506090 EPB-348 has already demonstrated human clinical proof- of-concept efficacy against Epstein-Barr Virus (EBV) EPB-348 has excellent EBV activity • 10.20-fold more potent in vitro than acyclovir, penciclovir, or foscarnet Phase 2 study of EPB-348 for EBV infectious mononucleosis • Double-blinded, placebo-controlled • Patients received 2 g EPB-348 twice a day for 21 days • Primary endpoint: proportion of subjects with a 100-fold drop in EBV in oral washings EPES-348 Placebo P Oral supernataM (N=11) (N.10) value Number of subjects with 22 logg, decrease 8 1 0.008 In EBV copies/ml at end of treatment Median (mean) decrease in EBV viral load 3.11(2.82) 0.30(0.05) 0.000 during dosing period 22 22 EFTA00506091  2013-08-22 EPB-348 significantly reduced EBV load in a Phase 2 infectious mononucleosis trial Oral Supernatant Time to < 1000 copies/mL Oral Sup 150 Placebo I0 Vaixnecclov • 0 3. O 3 1 100 co ig° gEe 2 A 50 _a C tl t p -0 04 0 10 15 10 201 30 40 I Study pay Days 1 21 Day Treatment Mabel I Fallow Up period fro drug) ICIAC 2009 2;1 23 EFTA00506092 EPB-348, transplant, & Epstein-Barr Virus (EBV) Background • EBV-driven diseases such as Post-Transplant Lymphoprotiferative Disorder (PTLD), EBV-encephalitis, and EBV-pneumonitis are important complications following organ transplantation and can result in significant morbidity and mortality • ND antiviral approved for EBV — no competition, first to market • EBV-driven transplant diseases are eligible as an orphan indication • Additionally, Varicella-zoster virus (WV) frequently causes severe infections in patients who have undergone bone marrow transplantation. EPB-348 and EBV • EPB-348 to be used to treat or prophylaxis for at-risk transplant patients EBV-Transplant Infections and Complications • Over 28,000 solid organ transplants and 10,000 bone marrow transplants in US annually • Early sales possible via Named Patient Program • Potential market of approximately $200 million in the US . Comparable: vaigancicimir Wall had sales of approx. $300 m in the us . 70% of Val sales were for transplant patients l$200 m) 24 24 EFTA00506093  EBV-Transplant Phase 2 Trial (EPB-348) Design & Milestones Screening/ 21-day 35.day Randomization treatment I I follow-up EPB 348 Treatment 2g BID Regimen Study Design • Double-blinded, placebo controlled Placebo • 40 transplant recipients with EBV wernia BID • Primary Endpoint: Virologk response to therapy Milestones • 12-month enrollment period • 2 month subject participation period • 1.5-Month from cast patient out to database lock • 1.5-Month from database lock to topline data Success Factors • utilizing established clinical network of well-respected, high-volume centers in US and Canada • Objective endpoint: Viroklk response to therapy • EPB-348 has already proven to be a potent anti-EBV agent in the previous infectious mononucleosis - therefore, high likelihood of success to reduce EBV (as well as VZV) in viremia transplant patients 25 EFTA00506094 Valomaciclovir Stearate (EPB-348) Additional Indications: Autoimmune & Proliferative Diseases Impacted By EBV Epiphany Biosciences 26 EFTA00506095  EPB-348 for orphan autoimmune & proliferative diseases impacted by herpesviruses (EBV, HSV-1) Background • EBV appears to play an etiological and/or exasperating role In a number of rare, but serious and life-threatening diseases, including: • Multiple Sclerosis, Idiopathic Pulmonary Fibrosis, & Nasopharyngeal Carcinoma EMI-348 and EBV-AutoimmuneAymphoproliferative disease • These indications offer potential significant add-on upside for EPS-348as well as representing a paradigm-changing therapeutic approach to a variety of serious diseases, many of which have orphan status • Chronic toxicity studies required prior to trials with longer-term EP8-348 dosing Multiple market opportunities In orphan diseases • Multiple Sclerosis (MS) • US prevalence of approx. 400,000 patients; Potential market of approx. $1.5.3 billion based on Copaxone, Avonex, & Rebif comparables • ldlopathk Pulmonary Fibrosis (IPF) • US incidence of approx. 20,000-50,CCOcases annually; Global market was valued at $2 billion in 2009 • Nasopharyngeal Carcinoma (NPC) • Accounts for 18% of all cancers in China; Global market of approx. $50-200 million 2 27 EFTA00506096 EPB-510 for Hepatitis C (HCV) Preclinical Nucleotide Polymerase Inhibitor (NPI) Program propar*CoebteVal ...3.104.0.11aget 28 EFTA00506097  EPB-510 is a highly differentiated approach to HCV Nucleotide Polymerase Inhibitors (NPIs) • Recent data from 2012 AASID confirm the critical role NPIs will play as the cornerstone of future DAA therapies for HCV • HCV nucleotide polymerase inhibitors have clustered around a narrow set of structures based primary on 2'-substituted ribose • Very limited IP room to operate • Members of this class have been withdrawn because of toxicity and/or lack of activity • However, acyclic nucleosides have a long history of success and safety in the clinic as antiviral agents against herpes virus, HIV, and HBV • Valtrex, acyclow, & Famvir • Epiphany is developing EPB-510 as the first acyclic nucleotide polymerase family to target HCV • Epiphany controls IP around EPB-510, a new class of nucleotide-like polymerase inhibitors • Combination of novel scaffold and pro-drug technology • Orally bioavailable pro.drug designed to be liver targeting 29 29 EFTA00506098  EPB-510 has an highly competitive in vitro & in vivo profile for an HCV NPI 100 Discovery & Development Resistance 84621 • Epiphany discovered ENS-510 as part of its Internal analogue Mutant development program ä 10 « Acthnly Competitive activity profile • EPB-510 has sub-pM in vitro HCV replicon activity 3 • Rang of actmtrmry similar to other UPIs enduring GS.7977 • Series Is equipotent against GT la & lb al • Unique resistance pattern compared to G5-7977 & INX-08189 • 5282T muldon associated with resistance to T-C-rnethylated compounds 'ZOO (2*CrneCI • Myntmal loss of actmty apest 528211455P mutant ICUregimens 2 1000 IT. gee Excellent Pit and safety profile E • EPB-510 is orally bioavailable and well-tolerated In vivo • Achieves plasma levels well in excess of therapeutic dose (ECso) • Metabolitefs) derived from pro-drug highly unlikely to pose toxicity 200 Issue 0 TOW Cre 30 EFTA00506099  EPB-510 Value Proposition New NPI's are desired for HCV • Next-generation HCV DAA cocktails will likely utilize an NPI • Well-established comparables for preclinical and clinical stage NPIs EPB-510 has a competitive NPI profile • Unique and differentiated approach to NPIs • EPB-510 has excellent HCV replicon NPI activity • Preliminary in vitro pharmacology and toxicity studies complete • Scalable synthetic route developed Clear route to clinic • IND-enabling studies can be completed in approximately 6 months • Proof-of-Concept Phase lb in approximately 9.10 months after IND Strategic objective • Following positive Phase lb data, seek licensing partner for development through Phases 2 & 3 or sell asset 31 EFTA00506100  Epiphany Biosciences Corporate Highlights = Milestones, Team, & Value Proposition ___ 31 IIIM 32 EFTA00506101  Anticipated Value-Driving Milestones EPB-348 P2bIn %kW ta CMGTMCad Ph26/3 Shingles Pain Trial P2INITni MIMS KO MeinLa* I Ph/ EBV.Transplant Trial Eatrats.CHsianarstar0 03V.Trae Only, OvaCgari P2 'AVM/din Ph2 EBV.Autoimmune Trul EBYktahrnne P2TNl by EPB-510 PlatialhdalCV EAU 2016 creowno Ph la/b HCV Trial Mitch: Dr FIOLHIPowih Q4 2013 Q12014 Q22014 Q32034 Q42014 33 EFTA00506102  Epiphany has a very experienced team • Fred Volirtsky, MD, Founder, Chairman & CEO . Co-founded Colherix (acquired by Actelion for S430m); member Ballard Life Science Fund LAB • Previously Managing Director at ACT BioYentures • Held Directorships at Myornetrix,Ckterie Pharma, Imagine Pharma, Kerberos Proximal Solutions, Catalyst Biosdences • Former faculty member at Harvard Department of Emergency Medicine • Howard I. Woman, MD, Chief Medieol & Seientific Consultant (Prof. of Medicine, Pathology, Cell Biology, Columbia University' • Steven Day,PhD, Director of Chemistry ( 15. years of drug discovery & development experience- Kosan Biosciences) • Curtis Saibner, MD, MBA, Regulatory Affairs 127+ years regulatory covalence; former Medical Officer & Dep. Director at FDA) • Paul Flyer, PhD, Dinka(Stansacs 135• years of statistical experience - FDA, Amgen, Biogen Ides. ICOS) • Solomon Tse, PhD, Chemistry, Manufacturing, & Controls (30• years OMC experience- MJ) • Dan Szeto, PhD, OA/QC pa years QC/QA/GMP/GLP operations experience - Elan) • Chin-doing Lin, PhD, PrechhicalDevercipment (35• years preclinical development experience - YaleaM,101. ScheringPloughl • Michael Farber, PhD, JD, MtellectualProperty (27+ years IPexperience, Partner at Ditthavong Mod & Steiner) Senior Advisory Board • Robert Gallo, MD, Founder & SAB Chairman (Co-discoverer of HIV Lasker Award Laureate; Founder & Director of HIV) • Roger Komberg, PhD, (2006 Nobel Laureate in Chemistry, Tem Board Member, Prof. Stanford University) • Yuan Chang, MD. (Discoverer of two of the seven known human cancer viruses, Universityof Pittsburgh Cancer Institute) 34 34 EFTA00506103  2013-08-22 Epiphany Biosciences' Value Proposition • Late-stage clinical antiviral company with two attractive, high-potential candidates • EPB-348 is a proven drug candidate with multiple "shots-on-goal" • Safe and effective small molecule with broad spectrum antiviral activity • Pin competition for unmet medical needs • No antiviral approved for shingles associated pain • No approved antivirals for EBV • Paradigm-changing therapeutic approach to a variety of serious diseases, intl. orphan indications • EPS-510 is a Nucleotide Polymerase Inhibitor (NPI) for HCV with a highly competitive preclinical profile versus other high profile leading NPIs • Streamlined and efficient development and clinical plans • Able to achieve major value-inflection points in multiple clinical programs in approximately 1.2 years • Highly experienced team with track record of success 35 Add spreadsheet details 35 EFTA00506104  2013-08-22 The ofonnatbn cornered in On Ommeal b<MIgeMW and monetary to tOO/IMy boxicaces, Fa, asiptwtil 4n, irillardetery fer tho pent.% le itheen 4 is LrbniasellS by Ippliany. and erib to *lbw thou.Inenr to rata • pasta, nant-4 on Etiuw,r EPOSAy mabas no trepnewati0ora or vaevanInt. gipra cc orcils4 n to the soonatv a <cmdelmers ce die Sonkilka conizon. teWF. WIN*. Ois doonital boveghtte recnny ol (Want ACC0nIn(h. •ry opeeduttea el tin oxymora.n•hol• or el Pat or tly 6.vMlar d nv rformat cn Jinn witieut M1r prix vaRts, <msmtd PPNIM..l MACON, O Implutry elonlllus. Inc 2C06- 1013 36 EFTA00506105